Related Experiment Video
Updated: Jun 7, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
C B Confavreux1, R D Chapurlat
1Department of Rheumatology, INSERM U831-Université de Lyon, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon 69003, France. cyril.confavreux@inserm.fr
Abstract:
Inflammatory joint diseases are responsible of chronic systemic inflammation, joint degradations, deformities, and altered quality of life. Patients suffering from chronic rheumatic diseases also present increased bone fragility and increased fracture risk. Registration of biologic therapies has deeply modified care in rheumatic diseases, especially in rheumatoid arthritis and ankylosing spondylitis. The available biologics are the anti proinflammatory cytokine therapies (TNFα blockers, anakinra and tocilizumab) and the biologics active on T cell activation (abatacept and rituximab). These drugs succeeded in blocking disease activity and joint degradation. They are also able to stop systemic bone loss among patients with inflammatory rheumatic diseases. In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
The Functions of the Skeletal System
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Osteoclasts in Bone Remodeling

